


- 38 -

Claims

1. A compound of the formula:



- 5 and the pharmaceutically acceptable salts thereof

wherein Ar¹ is indole, benzimidazole, or benzotriazole, optionally substituted with lower alkyl (1-4C), halo, or lower alkoxy (1-4C);

X¹ is CO or an isostere thereof;

Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl;

n is 0 or 1;

Z is CH or N;

X² is CH, CH₂ or an isostere thereof; and

Ar² consists of one or two phenyl moieties directly coupled to X² and optionally

substituted by halo, nitro, alkyl (1-6C), CN or CF₃, or by RCO, COOR, CONR₂, NR₂, OR or SR, wherein R is H or alkyl (1-6C) or by phenyl, itself optionally substituted by the foregoing substituents;

with the proviso that if Z is N, X¹ is CO, and Ar¹ is indole, Ar¹ must be coupled to X¹ through the 2-, 5-, 6- or 7-position.

2. The compound of claim 1 wherein n is 0.

3. The compound of claim 1 wherein Z is CH.

4. The compound of claim 3 wherein X¹ is CO.

- 39 -

- 5
5. The compound of claim 3 wherein Ar¹ is indole or benzimidazole.
6. The compound of claim 3 wherein n is 0.
7. The compound of claim 3 wherein Ar¹ is coupled to X¹ through the 3, 4, 5 or 6 position.
8. The compound of claim 3 wherein X² is CH and Ar² consists of two optionally substituted phenyl moieties.
9. The compound of claim 3 wherein X² is CH₂ or CO and Ar² consists of one optionally substituted phenyl moiety.
10. The compound of claim 3 wherein Ar² is phenyl optionally substituted with halo.
11. The compound of claim 1 wherein Ar¹ is coupled to X¹ through its 5-position.
12. The compound of claim 11 wherein X¹ is CO.
13. The compound of claim 11 wherein n is 0.
14. The compound of claim 11 wherein Ar¹ is optionally substituted indole or benimidazole.
15. The compound of claim 11 wherein Ar¹ is optionally substituted indole.

- 40 -

16. The compound of claim 11 wherein X^2 is CH_2 or CO and Ar^2 consists of one optionally substituted phenyl moiety.

5 17. The compound of claim 11 wherein Ar^2 is phenyl optionally substituted with halo.

18. The compound of claim 1 wherein Ar^1 is optionally substituted indole and Z is CH.

10

19. The compound of claim 18 wherein Ar^1 is unsubstituted indole.

20. The compound of claim 18 wherein X^1 is CO.

15

21. The compound of claim 18 wherein n is 0.

22. The compound of claim 18 wherein Ar^1 is coupled to X^1 through the 3, 4, 5 or 6 position.

20

23. The compound of claim 18 wherein X^2 is CH and Ar^2 consists of two optionally substituted phenyl moieties.

24. The compound of claim 18 wherein X^2 is CH_2 and Ar^2 consists of one optionally substituted phenyl moiety.

25

25. The compound of claim 18 wherein Ar^2 is phenyl optionally substituted with halo.

- 41 -

26. The compound of claim 1 wherein Ar¹ is optionally substituted benzimidazole.

27. The compound of claim 26 wherein X¹ is CO.

28. The compound of claim 26 wherein n is 0.

29. The compound of claim 26 wherein Ar¹ is coupled to X¹ through the 3, 4, 5 or 6 position.

30. The compound of claim 26 wherein X² is CH and Ar² consists of two optionally substituted phenyl moieties.


31. The compound of claim 26 wherein X² is CH₂ and Ar² consists of one optionally substituted phenyl moiety.

32. The compound of claim 26 wherein Ar² is phenyl optionally substituted with halo.

33. The compound of claim 1 which is 4-benzylpiperidinyl-indole-5-carboxamide or is 4-benzylpiperidinyl-benzimidazole-5-carboxamide.

34. A method to treat a condition characterized by a proinflammation response which method comprises administering to a subject in need of such treatment a compound of the formula

- 42 -



or a pharmaceutically acceptable salt thereof

wherein Ar^1 is indole, benzimidazole, or benzotriazole, optionally substituted with lower alkyl (1-4C), halo, or lower alkoxy (1-4C);

5 X^1 is CO or an isostere thereof;

Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl;

n is 0 or 1;

Z is CH or N;

10 X^2 is CH, CH_2 or an isostere thereof; and


Ar^2 consists of one or two phenyl moieties directly coupled to X^2 and optionally substituted by halo, nitro, alkyl (1-6C), CN or CF_3 , or by RCO, COOR, CONR_2 , NR_2 , OR or SR, wherein R is H or alkyl (1-6C) or by phenyl, itself optionally substituted by the foregoing substituents;

15 with the proviso that if Z is N, X^1 is CO, and Ar^1 is indole, Ar^1 must be coupled to X^1 through the 2-, 5-, 6- or 7-position.

35. The method of claim 34 wherein said condition characterized by inflammation is acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, uveitis, IBD, acute renal failure, head trauma, or ischemic/reperfusion injury.

36. A method to treat a heart condition associated with cardiac failure which method comprises administering to a subject in need of such treatment a compound of the formula

- 43 -



or a pharmaceutically acceptable salt thereof

wherein Ar^1 is indole, benzimidazole, or benzotriazole, optionally substituted with lower alkyl (1-4C), halo, or lower alkoxy (1-4C);

5 X^1 is CO or an isostere thereof;

Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl;

n is 0 or 1;

Z is CH or N;


10 X^2 is CH, CH_2 or an isostere thereof; and

Ar^2 consists of one or two phenyl moieties directly coupled to X^2 and optionally substituted by halo, nitro, alkyl (1-6C), CN or CF_3 , or by RCO, COOR, CONR_2 , NR_2 , OR or SR, wherein R is H or alkyl (1-6C) or by phenyl, itself optionally substituted by the foregoing substituents.

15

37. The method of claim 36 wherein said chronic heart condition is congestive heart failure, cardiomyopathy or myocarditis.

38. -- A method to prepare a compound of the formula



20

or a pharmaceutically acceptable salt thereof

wherein Ar^1 is indole, benzimidazole, or benzotriazole, optionally substituted with lower alkyl (1-4C), halo, or lower alkoxy (1-4C);

X¹ is CO or an isostere thereof;

Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl;

n is 0 or 1;

5 Z is CH or N;

X² is CH, CH₂ or an isostere thereof; and

Ar² consists of one or two phenyl moieties directly coupled to X² and optionally substituted by halo, nitro, alkyl (1-6C), CN or CF₃, or by RCO, COOR, CONR₂, NR₂, OR or SR, wherein R is H or alkyl (1-6C) or by phenyl, itself optionally substituted by the


10 foregoing substituents;

which method comprises

(a) reacting a compound of the formula




with a compound of the formula



under conditions wherein the carboxamide is formed; or

(b) reacting an optionally substituted indole, benzimidazole or benzotriazole


with a compound of the formula



wherein L is leaving group; or

(c) reacting a compound of the formula

- 45 -



with a compound of the formula



wherein M is a halide,

under conditions of mild base.

5